Feasterville, PA

Nancy Ward

Diabetes and Endocrinology Consultants of Pennsylvania, LLC

Diabetes Mellitus

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Overweight

Cardiovascular Diseases

Lorcaserin HCl

BELVIQ

Tirzepatide

LY3298176

Lilly

AstraZeneca

Eisai

GlaxoSmithKline (GSK)

LabStyle Innovations

Medtronic

Senseonics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Diabetes and Endocrinology Consultants of Pennsylvania, LLC | Feasterville, PA

Site insights

Contact this site

Active trials

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

Trial sponsors